3Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Debra Kain ddkain@ucsd.edu 619-543-6163 University of California - San Diego Using imaging mass spectrometry, researchers at the University of California, San Diego have developed tools that will enable scientists to visualize how different cell populations of cells communicate. Their study shows how bacteria talk to one another - an unde…
+Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Emil Venere venere@purdue.edu 765-494-4709 Purdue University WEST LAFAYETTE, Ind. - Researchers at Purdue University have discovered a new approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres that could be injected into the blood shortly after an accident. The synthetic “copolymer micelles&…
3Vote!
Life Science World (Free subscription) | yesterday
[NEWS] Contact: Glenna Picton picton@bcm.edu 713-798-4710 Baylor College of Medicine HOUSTON - (Nov. 8, 2009) - The loss of a gene through deletion of genetic material on chromosome 15 is associated with significant abnormalities in learning and behavior, said a consortium of researchers led by Baylor College of Medicine (<a href=”http://w…
3Vote!
Bellwether Green Supply Chain (Free subscription) | yesterday
The Guardian and Cleantech Group recently announced the Global Cleantech 100. The Most Promising Water and Wastewater Treatment Company http://cleantech.com/news/4970/water-and-wastewater# Several of The Most Promising Solar Companies Concentrix Solar Freiburg, Germany, Product description: Concentrator photovoltaics Enphase California, US, Product description: Solar microinverters G24 Innovations...
3Vote!
PR News Wire (Free subscription) | yesterday
CAMBRIDGE, Mass., Nov. 7, /PRNewswire/ -- Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school science competition....
+Vote!
PR News Wire (Free subscription) | 07/11/2009
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Early...
+Vote!
PR News Wire (Free subscription) | 07/11/2009
MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients...
+Vote!
Fight Aging! (Free subscription) | 07/11/2009
Some people have better genes than other people; such is the luck of the draw. The effects of most genetic differences on human longevity appear to be small in comparison to the effects produced by lifestyle choices, however. You are still the master of your own destiny in that regard. Time wasted in wishing you had a better variant of FOXO3A would be better spent exercising. A great deal of modern...
+Vote!
Seattle Times (Free subscription) | 07/11/2009
A federal court judge in Tennessee has lifted temporary restraining orders that barred ZymoGenetics from making certain claims in its marketing of the blood-clotting agent Recothrom, the Seattle-based biotechnology company said Friday.
3Vote!
Drug Injury Watch (Free subscription) | 06/11/2009
TREAT Study Revealed, Also, That This Amgen Anemia Drug Was No Better Than Placebo In Reducing Deaths Or Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) The anemia drug Aranesp (darbepoetin alfa) might cause an increased risk for stroke in patients with diabetes and chronic kidney disease, according to the results from the Trial to Reduce Cardiovascular Events with Aransep Treatment...
+Vote!
PR News Wire (Free subscription) | 06/11/2009
SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.
+Vote!
PR News Wire (Free subscription) | 06/11/2009
AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product...
3Vote!
Life Science World (Free subscription) | 06/11/2009
[NEWS] LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ — BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. “We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously reco…...
3Vote!
The IN VIVO Blog (Free subscription) | 06/11/2009
Sweden’s Biovitrum on November 5 stumped up just over half a billion dollars for compatriot Swedish Orphan, buying itself a tidy additional SEK800 million ($115 million) in revenues, an extended commercial network and a couple of near-term launch opportunities. The move is yet another step in Biovitrum’s transformation into a specialty pharma company—coming just a week after it offloaded...
Explore : AstraZeneca,
Biotechnology,
Channels,
Discovery,
Diseases,
Drug Manufacturers,
Health-Fitness,
Health Industries,
Primary Care,
Proximagen Neuroscience,
Wyeth
4Vote!
Nature (Free subscription) | 06/11/2009
Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months.